Equibles does not estimate personal net worth.
Get an email with a short summary when Johnson & Johnson publishes a filing, an earnings call transcript or a press release.
Get JNJ alertsTim Schmid is recorded as Chairman at Johnson & Johnson (JNJ). Johnson & Johnson reported in an 8-K filed October 23, 2023 that Tim Schmid was appointed Executive Vice President, Worldwide Chairman of MedTech. Tim Schmid has spoken on 6 earnings calls and 1 other investor event across 1 company, most recently for Johnson & Johnson on October 13, 2026. Johnson & Johnson is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at Johnson & Johnson includes J. Wolk (CFO), D. E. Pinto (Board Member), Daniel Pinto (Board Member) and 7 others.
“Tim Schmid has been appointed Executive Vice President, Worldwide Chairman of MedTech, joining the Company’s Executive Committee.”
“So, Asad, ultimately, abiomed remained in a temporary headwind, as you saw in Q3, but our conviction in the long-term opportunity has not changed at all.”
“Certainly, given the hospital providers, our second quarter performance in context for you and for others. When we step back in the portfolio, the underlying picture remains solid.”
“As we referenced in Q1 of last year, which you will recall was entirely related to the items that occurred in 2024, year-over-year growth rate, creating a lighter comparator.”
“So quickly on the subsidies and put that one to bed. Firstly, you know, based on what we know, the loss of ACA subsidies or any potential policy changes under the one big beautiful bill to have a material impact on our med tech performance.”
SEC 8-K
2023-10-23–present
Drug Manufacturers - General · Healthcare
Chairman
2023-10-23–present
